Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cepheid Receives FDA Clearance For Xpert CT/NG, Delivering Rapid Detection And Differentiation Of Chlamydia And N. Gonorrhoeae


Thursday, 27 Dec 2012 04:10pm EST 

Cepheid announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert CT/NG. Running on Cepheid's GeneXpert Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States. 

Company Quote

53.21
0.42 +0.80%
9:48am EST